Mukka Proteins Q2 FY27 Revenue Up 108% to ₹5,088.7 Mn
Mukka Proteins reported a strong Q2 FY27 with consolidated revenue soaring 108.06% year-on-year to ₹5,088.70 Mn. Profit After Tax (PAT) also saw significant growth, increasing by 157.51% YoY to ₹177.27 Mn. This performance was driven by robust export demand, improved realisations, and favourable industry dynamics, despite some geopolitical and supply-chain disruptions deferring certain shipments. Key business highlights include the commencement of commercial production at the Oman facility, increasing total capacity to 340,170 MTPA, USDA NOP Inputs Attestation for their organic fertilizer, and U.S. FDA facility registration, which strengthens market access. CARE Ratings revised the outlook to Stable from Negative, reflecting improved operating performance.
Key Highlights
- Q2 FY27 consolidated revenue surged 108.06% YoY to ₹5,088.70 Mn.
- PAT grew 157.51% YoY to ₹177.27 Mn in Q2 FY27.
- Oman facility commenced commercial production, boosting capacity.
- Secured U.S. FDA facility registration and USDA NOP attestation.
- CARE Ratings revised outlook to Stable from Negative.
Price Impact
More from MUKKA